81 related articles for article (PubMed ID: 15779381)
1. [Pathophysiological conditions progressing from impaired glucose tolerance: atherosclerosis].
Yokote K; Saito Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():250-4. PubMed ID: 15779381
[No Abstract] [Full Text] [Related]
2. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
3. [Treatment for coronary artery disease patients with impaired glucose tolerance].
Kume A; Miyazaki T; Daida H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():543-7. PubMed ID: 15779438
[No Abstract] [Full Text] [Related]
4. [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Tomono S; Uchiyama T; Ohyama Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():255-9. PubMed ID: 15779382
[No Abstract] [Full Text] [Related]
5. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
6. [Impaired glucose tolerance in patients with ischemic heart diseases].
Yasuda S; Miyazaki S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():300-2. PubMed ID: 15779392
[No Abstract] [Full Text] [Related]
7. [Heart failure and abnormal glucose metabolism].
Jiyoong K; Kitakaze M
Nihon Rinsho; 2007 May; 65 Suppl 5():581-7. PubMed ID: 17569330
[No Abstract] [Full Text] [Related]
8. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
9. [Pathophysiological conditions progressing from impaired glucose tolerance: stroke (cerebral infarction)].
Kiyohara Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():260-3. PubMed ID: 15779383
[No Abstract] [Full Text] [Related]
10. [Glucose intolerance: postprandial hyper glucose, risk factor for diabetic macroangiopathy].
Igarashi Y; Kawamori R
Nihon Rinsho; 2006 Nov; 64(11):1998-2004. PubMed ID: 17087289
[TBL] [Abstract][Full Text] [Related]
11. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
12. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
Swanson A; Watrin K; Wilder L
J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
[TBL] [Abstract][Full Text] [Related]
13. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
Nishimura R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
[No Abstract] [Full Text] [Related]
14. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
15. [Alpha glucosidase inhibitor].
Katsuta H; Ishida H
Nihon Rinsho; 2006 Dec; 64 Suppl 9():637-45. PubMed ID: 17458296
[No Abstract] [Full Text] [Related]
16. Alpha-glucosidase inhibitors: new therapeutic agents for chronic heart failure.
Node K
Hypertens Res; 2006 Oct; 29(10):741-2. PubMed ID: 17283858
[No Abstract] [Full Text] [Related]
17. [Short term assessment of anthropometric indices and metabolic parameters in obese subjects treated with acarbose].
Coli P; Pea E; Lacorte M; Passaglia C; Carrai M
Minerva Med; 1996 Apr; 87(4):161-70. PubMed ID: 8700340
[TBL] [Abstract][Full Text] [Related]
18. Alpha-glucosidase inhibitors may reduce the risk of type 2 diabetes.
Servey JT
Am Fam Physician; 2007 Aug; 76(3):374-5. PubMed ID: 17708136
[No Abstract] [Full Text] [Related]
19. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
[TBL] [Abstract][Full Text] [Related]
20. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
